RxDoctor Payments Data

Sol Harari, MD

Family Medicine · Ft Lauderdale, FLNPI 1629066741

Payments from drug & device makers

$2,714in general payments, 2019–2025

Across 130 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$652
  • Lilly USA, LLC$325
  • Pfizer$299
  • Bayer$224
  • Idorsia Pharmaceuticals US Inc$186
  • AstraZeneca$174
  • plus $854 from 17 others

What the payments were for

  • Food & beverage$2,714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,714 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$47,868
Medicare patients
110
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$80,600
OzempicSemaglutide70$72,728
XareltoRivaroxaban40$32,720
RybelsusSemaglutide20$23,119
FarxigaDapagliflozin Propanediol25$20,981
MounjaroTirzepatide16$16,312
Albuterol Sulfate HfaAlbuterol Sulfate164$4,635
Fluticasone Propionate375$4,627
Omeprazole483$3,863
Atorvastatin Calcium486$3,060
SynthroidLevothyroxine Sodium37$2,860
Rosuvastatin Calcium295$2,300
Levothyroxine Sodium191$1,765
Azelastine Hcl68$1,751
Metoprolol Succinate194$1,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$652$95,84790 claims
PfizerEliquis$299$80,60095 claims
Johnson & JohnsonXarelto$91$32,72040 claims
AstraZenecaFarxiga$174$20,98125 claims
Lilly USA, LLCMounjaro$325$16,31216 claims
AbbVieSynthroid$72$2,86037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →